Objectives: Increasing numbers of miltefosine treatment failures in visceral leishmaniasis therapy and reports of miltefosine resistance in the Indian subcontinent resulted in the recommendation to use liposomal amphotericin B as first-line therapy. Cross-resistance between miltefosine and amphotericin B has recently been documented, suggesting a role of mutations in the miltefosine transporter, a complex encoded by the MT and ROS3 genes. This study aimed to further explore the putative role of MT/ROS3 defects in the molecular basis of amphotericin B cross-resistance.
Introduction
Miltefosine was introduced as first-line therapy against visceral leishmaniasis (VL) in the Indian subcontinent in 2002 to combat the growing incidence of antimony resistance. 1 Since then, the number of treatment failures has steadily increased and reports have emerged of the few first miltefosine-resistant isolates.
2,3
Previous work using both experimentally derived resistant isolates and a miltefosine-resistant clinical Leishmania infantum isolate demonstrated the involvement of mutations in the inward miltefosine transporter (MT) and its subunit ROS3 affecting effective drug uptake. 4, 5 Although cross-resistance between amphotericin B and other anti-leishmanial drugs has been suggested, 6 evidence for the association between miltefosine and amphotericin B resistance is still scarce and mutations in the MT complex have so far never been directly linked to amphotericin B resistance.
3,7-11
A recent study did, however, associate mutations in the MT complex with alterations in the lipid composition of the plasma membrane with subsequent cross-resistance to amphotericin B. 12 Given the recent shift towards a single dose of liposomal amphotericin B followed by a short course of miltefosine as first-line treatment in the Indian subcontinent, 13 combined with the recent reports mentioning not only the emergence of miltefosine resistance, 3 but also of clinical amphotericin B resistance, 7 investigation into a possible link between miltefosine and amphotericin B resistance becomes highly relevant. Hence, this in vitro study evaluated the amphotericin B susceptibility of a laboratory-derived and a clinical miltefosine-resistant isolate characterized by having defective MT and/or ROS3, and investigated whether their reconstituted knockin transfectants restored miltefosine susceptibility.
Materials and methods

Ethics
Experiments using laboratory rodents were carried out in strict accordance with all mandatory guidelines (European Union directives, including Revised Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes that came into force on 01/01/2013, and the Declaration of Helsinki in its latest version) and was approved by the Ethics Committee of the University of Antwerp, Belgium (UA-ECD 2011-17). 
Chemical compounds
Miltefosine (hexadecylphosphocholine, Carbosynth, Berkshire, UK) was dissolved in MilliQ water at 20 mM (compound stock solution) and stored at 4 C. Amphotericin B deoxycholate (Fungizone V R , Bristol-Myers Squibb, Braine-l'Alleud, Belgium) and liposomal amphotericin B (AmBisome V R , Gilead Sciences, CA, USA) were freshly dissolved on the day of the experiment at 5.4 mM (Fungizone V R ) and 6.4 mM (AmBisome V R ) in a 5% dextrose solution in MilliQ water.
Leishmania strains
The potential cross-resistance between amphotericin B and miltefosine was evaluated on a previously described panel of L. infantum strains:
4 (i) MHOM/ FR/96/LEM3323 and the naturally miltefosine-resistant MHOM/FR/2005/ LEM5159, which were both isolated from French HIV-positive patients who underwent several rounds of amphotericin B and/or miltefosine treatment, 14 and were kindly provided by Dr Laurence Lachaud (Laboratoire de Parasitologie-Mycologie et Centre National de Référence des Leishmanioses, Montpellier, France); (ii) the laboratory-selected miltefosine-resistant LEM3323-MIL; and (iii) the episomally transfected LEM3323-MIL ! LiMT and LEM5159 ! LiROS3, which both show a restored miltefosine susceptibility. Promastigotes were grown in HOMEM (Gibco V R , Life Technologies, Ghent, Belgium) supplemented with 200 mM L-glutamine, 16 .5 mM NaHCO 3 , 10% heat-inactivated FCS, 40 mg/L adenine, 3 mg/L folic acid, 2 mg/L D-biotin and 2.5 mg/L haemin at 25 C and were subcultured twice weekly. Transfectants were grown under hygromycin pressure.
Drug susceptibility assays
In vitro promastigote and amastigote susceptibility to miltefosine and amphotericin B was evaluated as described earlier. 15 In brief, IC 50 values of log-phase promastigotes were determined by exposing the parasites to 2-fold serial drug dilutions starting from 40 lM miltefosine or 8 lM amphotericin B. After 72 h incubation, susceptibility of promastigotes was determined by viability testing upon addition of resazurin and fluorescence reading (Tecan V R , GENios). Promastigote susceptibility to AmBisome V R was not determined as this formulation specifically targets the macrophage. For amastigote susceptibility, primary peritoneal mouse macrophages were seeded into a 96-well plate in RPMI-1640 culture medium (Gibco V R , Life Technologies) at a concentration of 30000 cells/well, infected 24 h later with stationary-phase promastigotes (multiplicity of infection 10:1) and exposed to 2-fold serial drug dilutions. After 4 days, the infected macrophages were fixed with methanol and stained with Giemsa. Amastigote susceptibility was microscopically determined by comparing the intracellular amastigote burdens between treated and untreated cells. Cut-off values for resistance were set at 15 lM for miltefosine and 2 lM for amphotericin B. 16 
Results
Despite their previously confirmed differences in miltefosine susceptibility resulting from characterized genetic alterations in the MT gene (LEM3323-MIL) or the ROS3 gene (LEM5159), 4 all L. infantum strains maintained full susceptibility to amphotericin B both as promastigote (Table 1 ) and amastigote (Table 2) . Episomal reconstitution with WT MT or ROS3 of the respective miltefosineresistant strains restored miltefosine susceptibility, but did not affect the amphotericin B resistance profile (Tables 1 and 2 ).
Discussion
Identifying potential cross-resistance mechanisms in VL treatment becomes increasingly essential given the current recommendations towards combination therapy. 17 In the Indian subcontinent, a current option is based on combination of a single injection of liposomal amphotericin B and a short 5 day course of oral miltefosine. 13 Although resistance to either one of the drugs alone might emerge upon its recurrent application in the field, past research on antimony-resistant clinical isolates already identified potential acquisition of resistance to both miltefosine and amphotericin B. 6 While miltefosine resistance has been linked to mutations in the MT/ROS3 transporter machinery responsible for its inward transport, 5 amphotericin B resistance has been associated with an altered sterol composition and membrane fluidity. 7 No definite link between the miltefosine translocation machinery and amphotericin B has yet been identified, suggesting the involvement of other mechanisms. 18 A recent experimental selection of amphotericin B and miltefosine resistance on promastigotes revealed a low-level cross-resistance between miltefosine and amphotericin B next to MT mutations, but a functional link between these MT mutations and amphotericin B resistance was not fully substantiated and the observed cross-resistance was attributed to changes in the membrane lipid composition. 12 In that particular study, reconstitution of the amphotericin B-resistant strain with a functional MT only had a very moderate impact on restoration of amphotericin B susceptibility. Moreover, the amphotericin B-resistant line was not substantially hampered in miltefosine-uptake suggesting that the mutated MT was still functioning normally, casting doubt on the role of MT in the lowlevel amphotericin B cross-resistance feature described in that study. 12 The objective of the present study was to evaluate two genotypically and phenotypically characterized miltefosine-resistant L. infantum strains for their susceptibility to amphotericin B, both at promastigote and intracellular amastigote level. In spite of the confirmed mutations in the MT/ROS3 transporter complex and their defective miltefosine uptake, 4 no cross-resistance to amphotericin B could be demonstrated. This absence of crossresistance to amphotericin B is reassuring and refutes the direct involvement of the MT/ROS3 transporter complex in amphotericin B cross-resistance. As point mutations in the MT gene do not necessarily lead to functional changes in the transporter complex,4 it is more likely that one of the ample non-synonymous mutations or ploidy changes that were observed upon miltefosine-resistance selection may in fact be responsible for the described amphotericin B/miltefosine cross-resistance. To further evaluate a potential synergistic involvement of MT mutations and to identify other key genetic alterations involved in amphotericin B/miltefosine cross-resistance, Results are expressed as mean IC 50 value (lM)+SEM and are based on three independent replicates run in triplicate.
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